Skip to content


Critical Care

Open Access

Blood glucose target in acute phase suggested by the analysis of the relationship between blood glucose profile and the severity of the diseases

  • M Hoshino1,
  • Y Haraguchi2,
  • K Oda1 and
  • S Kajiwara1
Critical Care201418(Suppl 1):P446

Published: 17 March 2014


Blood glucose (BG) control in acute illness improves outcome. However, how to manage BG levels, or BG target, is not clearly elucidated. In this study, the BG target was suggested by the analysis of the relationship between BG profile and the severity of the diseases.


Ninety-six patients were studied. The following parameters were calculated during the first week after ICU admission. (1) Maximum value of SOFA score (SOFAmax). (2) Mean, standard deviation, maximum, minimum, and difference of BG levels (BGm, BGsd, BGmax, BGmin, BGd (BGmax - BGmin), respectively). BG levels were measured basically every 6 hours. (3) Correlation between SOFAmax and BG parameters using two-dimensional (correlation coefficient rt) and linear regression analysis (rl).


(1) Mortality of the patients with SOFAmax 0 to 3, 4 to 5, 6 to 7, 8 to 9, and 10 or more were 0%, 14%, 23%, 40%, and 89%, respectively. (2) rt and rl (rt/rl) between SOFAmax and BG parameters: BGsd (0.49/0.36), BGmax (0.47/0.32), BGm (0.45/0.23), BGd (0.44/0.32), and BGmin (0.25/0.06). (3) BG ranges that indicate SOFAmax less than 5 calculated from the two-dimensional correlation curves between SOFAmax and BGsd, BGmax, BGm, and BGd were 35 ± 25, 250 ± 112, 150 ± 33, and 156 ± 115 mg/dl, respectively.


BG parameters except BGmin were two-dimensionally related to the severity. Therefore, a part of the severe patients seemed to have lower BG levels and lower BG variability. Targeting those BG parameters in early phase within the abovementioned levels was considered to link to better outcome.

Authors’ Affiliations

Shisei Hospital, Saitama, Japan
Keiyo Hospital, Tokyo, Japan


© Hoshino et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.